Synergy between the AKT/mTOR pathway and GC sensitivity has previously been explored based on the finding that rapamycin responses show a significant relationship to DEX-resistance signatures in primary specimens from ALL patients (Wei et al, 2006; Bornhauser et al, 2007). Here, AKT1 is linked to acute lymphoblastic leukemia.